---
title: "VK2735 in Chronic weight management: Oral small-molecule GLP-1 receptor agonists"
description: "Formulary evidence on VK2735 in Chronic weight management: Oral small-molecule GLP-1 receptor agonists. Topics: Orforglipron: FDA approval in April 2026, Orforglipron: FDA-approved indication and limitation of use, Orforglipron: administration with or without food and dosage escalation, Orforglipron: dosage modification with CYP3A4 inhibitors and inducers, and 4 further topics. 8 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/oral-small-molecule-glp-1-receptor-agonists"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Oral small-molecule GLP-1 receptor agonists

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Oral Small-molecule GLP-1 Receptor Agonists

<a id="topic-2.2.2.1.4-1"></a>

### Orforglipron: FDA approval in April 2026

> “INDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems.”
> “Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.”

Source: [Eli Lilly Foundayo approval announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)

<a id="topic-2.2.2.1.4-2"></a>

### Orforglipron: FDA-approved indication and limitation of use

> “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
> “Concomitant use with another GLP-1 receptor agonist is not recommended.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-3"></a>

### Orforglipron: administration with or without food and dosage escalation

> “Take FOUNDAYO orally once daily, with or without food.”
> “The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily.”
> “After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily.”
> “The maximum dosage of FOUNDAYO is 17.2 mg once daily.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-4"></a>

### Orforglipron: dosage modification with CYP3A4 inhibitors and inducers

> “Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO.”
> “The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor”
> “Avoid strong CYP3A4 inducers when taking FOUNDAYO.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-5"></a>

### Orforglipron: design and treatment discontinuation in the labeled trial of adults without diabetes

> “In Trial 1 patients were randomized in a 3:3:3:4 ratio to FOUNDAYO 5.5 mg once daily, 9 mg once daily, 17.2 mg once daily, or placebo once daily.”
> “The proportions of patients who discontinued trial drug in Trial 1 were 22%, 22%, and 24% for the 5.5 mg, 9 mg, and 17.2 mg once daily FOUNDAYO-treated groups, respectively, and 30% for the placebo-treated group.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-6"></a>

### Orforglipron: equivalence of trial capsule doses to approved tablet doses

> “The investigational capsule formulations of orforglipron (6 mg, 12 mg, and 36 mg) used in these trials are bioequivalent to the tablet doses (5.5 mg, 9 mg, and 17.2 mg)”

Source: [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)

<a id="topic-2.2.2.1.4-7"></a>

### Orforglipron: weight change in adults aged 65 years and older

> “In ATTAIN-1 and ATTAIN-2, 616 randomized participants were ≥65 years of age.”
> “At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)”

Source: [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)

<a id="topic-2.2.2.1.4-8"></a>

### Orforglipron: self-pay, commercial, and Medicare Part D prices

> “Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card.”
> “Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026.”

Source: [Eli Lilly Foundayo approval announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)

Additional sources: [Eli Lilly Foundayo coverage and savings (2026)](https://foundayo.lilly.com/hcp/savings-coverage)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
